Health Related Quality of Life of Youth and Young Adults With Hemophilia A
NCT01034904 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48
Last updated 2013-12-10
Summary
The relevance of the study will be in establishing whether Health Related Quality of Life (HRQoL) measures obtained repeatedly during hemophilia care are sensitive to significant changes in health or personal circumstances related to the transition from youth to adulthood. This may support the future use of HRQoL measures as part of routine care in order to identify important changes that are not detectible by other clinical means.
Conditions
Sponsors & Collaborators
-
CSL Behring
lead INDUSTRY
Principal Investigators
-
Jean St-Louis, MD · St. Justine's Hospital
Eligibility
- Min Age
- 14 Years
- Max Age
- 30 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-10-31
- Primary Completion
- 2013-07-31
- Completion
- 2013-11-30
Countries
- Canada
Study Locations
More Related Trials
-
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917 ·Status: COMPLETED ·Phase: PHASE3
-
Genetic Susceptibility to Factor VIII Inhibitors
NCT00344435 ·Status: COMPLETED
-
Canadian CHO-KLAT/H-FIT Study - Quality of Life of, and Burden of Caring for, Persons With Hemophilia
NCT06191068 ·Status: COMPLETED
-
Canadian Hemophilia Prophylaxis Study
NCT01085344 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
NCT00157053 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
NCT01626105 ·Status: UNKNOWN
-
Epidemiology and Immunology of Hemophilia A Inhibitors
NCT00005518 ·Status: COMPLETED
-
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
NCT00189982 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
NCT06104826 ·Status: NOT_YET_RECRUITING
-
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
NCT00178607 ·Status: COMPLETED
-
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4
-
Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia
NCT07099313 ·Status: RECRUITING
-
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
NCT02225483 ·Status: COMPLETED
-
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
NCT03405337 ·Status: COMPLETED
-
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A
NCT02093897 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
NCT02172950 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
NCT01486927 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Factor Product Utilization and Health Outcomes in Patients With Hemophilia
NCT02796222 ·Status: COMPLETED
-
Socialization of Adult Men With Congenital Hemophilia A or B
NCT01510418 ·Status: COMPLETED
-
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
NCT03876301 ·Status: COMPLETED
-
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
NCT04805021 ·Status: RECRUITING
-
Patient Reported Outcomes Burdens and Experiences - Phase 3
NCT03549858 ·Status: RECRUITING
-
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
NCT00989196 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B
NCT03623295 ·Status: COMPLETED